(Alliance News) - Fine Foods & Pharmaceuticals NTM Spa reported Wednesday that it reported a loss of EUR1.7 million as of June 30, an improvement from a loss of EUR6.0 million in the first half of 2022.

Consolidated revenues stood at EUR127.5 million, up 27 percent from EUR100.6 million as of June 30 last year.

Ebitda is EUR12.6 million, up 61% from EUR7.8 million from 2022. Ebitda margin improves to 9.9 percent from 7.8 percent last year.

Ebit was EUR400,000 from EUR500,000 as of June 30, 2022, due to the write-down made to the goodwill related to Pharmatek and which is part of the broader context of the reorganization of the cosmetics BU, which included, among others, the divestment of some business lines no longer considered strategic.

Fine Foods & Pharmaceuticals NTM closed Wednesday unchanged at EUR8.40 per share.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.